The European Medicines Agency (EMA) has rolled out new updates to its Guidelines on good pharmacovigilance practices (GVP), aiming to refine how drug safety is assessed for pregnant and breastfeeding women, as well as their children exposed in utero or through breastmilk. These changes, published on February 6, 2026, are bound to resonate strongly among pharmaceutical companies, healthcare providers, and patient advocacy groups focused on maternal and child health, likely sparking detailed discussions on safety surveillance priorities.
The latest document, released directly by EMA, serves as an introductory cover note to the GVP framework, with particular attention to final considerations for a highly sensitive population subgroup. By updating these guidelines, the EMA’s pharmacovigilance committee advances its remit of ensuring medicines safety across varied demographics.
This publication is a guiding document rather than enforceable legislation. It elaborates best practices and procedural considerations, aiming to standardize safety monitoring approaches across the European Union and beyond. The guideline sets out concrete expectations for data collection pertaining to in utero and breastmilk exposure, although it refrains from imposing rigid numerical targets or binding deadlines.
EMA’s policy orientation leans toward strengthening post-market surveillance mechanisms, emphasizing the identification and assessment of risks specifically for pregnant and breastfeeding women. This focus reflects an increasing regulatory trend to balance consumer protection, particularly for vulnerable populations, against the practical regulatory burden for pharmaceutical industry stakeholders.
pharmaceutical companies may face moderate increases in data collection and reporting responsibilities, while healthcare providers must integrate enhanced vigilance into clinical practice. Patients and advocacy bodies advocating for safer maternal health could view these steps positively, as a move toward more detailed safety insights. Meanwhile, national regulatory authorities will need to update their monitoring frameworks accordingly.
This update is the continuation of an ongoing EMA effort to refine pharmacovigilance standards. The Agency’s next steps likely include engaging with other EU regulatory bodies and member states to ensure coordinated implementation, with eventual feedback loops to further evolve the guidelines based on evolving scientific evidence and stakeholder input.
← Atlas › News